Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
63
FGEN Quote, Financials, Valuation and Earnings
Last price:
$0.51
Seasonality move
:
22.52%
Day range:
$0.40 - $0.48
52-week range:
$0.18 - $2.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.27x
P/B ratio:
--
Volume:
2.6M
Avg. volume:
1.3M
1-year change:
-37.02%
Market cap:
$48.4M
Revenue:
$147.8M
EPS (TTM):
-$1.23
Analysts' Opinion
-
Consensus RatingFibroGen has received a consensus rating of . The company's average rating is a based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, FibroGen has an estimated upside of 1983.33% from its current price of $0.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $0.48.
Fair Value
-
According to the consensus of 0 analysts, FibroGen has 1983.33% upside to fair value with a price target of $10.00 per share.
FGEN vs. S&P 500
-
Over the past 5 trading days, FibroGen has overperformed the S&P 500 by 45.13% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
FibroGen does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
FibroGen has grown year-over-year revenues for 3 quarters straight. In the most recent quarter FibroGen reported revenues of $46.3M.
Earnings Growth
-
FibroGen has grown year-over-year earnings for 1 quarter straight. In the most recent quarter FibroGen reported earnings per share of -$0.17.
Enterprise value:
32.1M
EV / Invested capital:
-0.25x
Price / LTM sales:
0.27x
EV / EBIT:
--
EV / Revenue:
0.18x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.25x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$138.4M
Return On Assets:
-33.69%
Net Income Margin (TTM):
-67.66%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
3.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $122.9M | $155M | $180M | $40.1M | $46.3M | |
| Gross Profit | $104.4M | $136.6M | $138.4M | $35.9M | $41M | |
| Operating Income | -$370.1M | -$281.2M | -$94.4M | -$50.9M | $1.8M | |
| EBITDA | -$352.6M | -$274.1M | -$99.9M | -$56.8M | -$12.2M | |
| Diluted EPS | -$3.89 | -$3.06 | -$1.23 | -$0.65 | -$0.17 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $737.5M | $573.4M | $474.2M | $364.1M | $244.5M | |
| Total Assets | $812M | $850.5M | $608.8M | $460.4M | $264.4M | |
| Current Liabilities | $118.3M | $209.3M | $252M | $209.4M | $190.5M | |
| Total Liabilities | $341.1M | $505.5M | $562.6M | $575.6M | $466.1M | |
| Total Equity | $470.9M | $345.1M | $46.3M | -$115.2M | -$201.7M | |
| Total Debt | -- | -- | -- | $71.7M | $72.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$148.4M | -$349.2M | -$125.9M | -$84.5M | -$8.4M | |
| Cash From Investing | $37.5M | $144.5M | $134.5M | $54.2M | $755K | |
| Cash From Financing | -$1.9M | $171.7M | -$506K | -$22K | -$127K | |
| Free Cash Flow | -$188.2M | -$351.8M | -$126.2M | -$85.2M | -$8.5M | |
FGEN
Sector
Market Cap
$48.4M
$45.6M
Price % of 52-Week High
16.38%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-0.68%
-0.74%
1-Year Price Total Return
-37.02%
-31.35%
Beta (5-Year)
0.823
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$0.37
200-day SMA
Sell
Level
$0.85
Bollinger Bands (100)
Buy
Level
0.34 - 0.42
Chaikin Money Flow
Sell
Level
-91.2M
20-day SMA
Buy
Level
$0.38
Relative Strength Index (RSI14)
Buy
Level
69.82
ADX Line
Buy
Level
19.66
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$0.36
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Sell
Level
-87.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-7.4415)
Sell
CA Score
(Annual)
Level (-6.018)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (8.1982)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Stock Forecast FAQ
In the current month, FGEN has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The FGEN average analyst price target in the past 3 months is $10.00.
-
Where Will FibroGen Stock Be In 1 Year?
According to analysts, the consensus estimate is that FibroGen share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About FibroGen?
Analysts are divided on their view about FibroGen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that FibroGen is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is FibroGen's Price Target?
The price target for FibroGen over the next 1-year time period is forecast to be $10.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is FGEN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for FibroGen is a . 0 of 0 analysts rate the stock a at this time.
-
How Can I Buy Shares Of FGEN?
You can purchase shares of FibroGen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase FibroGen shares.
-
What Is The FibroGen Share Price Today?
FibroGen was last trading at $0.51 per share. This represents the most recent stock quote for FibroGen. Yesterday, FibroGen closed at $0.48 per share.
-
How To Buy FibroGen Stock Online?
In order to purchase FibroGen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.46% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.66% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.53% over the past day.
